Seeking Alpha
Profile| Send Message|
( followers)  

All of these biotech companies have very substantial amounts of cash or cash equivalents on their balance sheets. They also have either little to no debt. Biotechs typically burn through cash and when they don't have enough on hand or have too much debt, it can lead to trouble quick, especially if a new drug doesn't pan out as promised. Some of these biotech stocks have dropped recently. Due to their extremely high cash balances, some of them might be lower risk biotech investments or potential rebound plays. These companies all have interesting products in the pipeline which could become major catalysts in the future. Here are the companies.

Synta Pharmaceuticals, Inc. (NASDAQ:SNTA), is trading around $5.45. Synta is a biotechnology company, based in California. These shares have traded in a range between $2.55 to $6.93 in the last 52 weeks. The 50 day moving average is $5.22 and the 200 day moving average is $4.14. SNTA is estimated to lose about $1.08 per share in 2011. You can see repeated insider buying here.

This company is working on HSP90 inhibitors, (Ganetespib) which has shown up to 100 times greater potency in killing cancer cells and an improved safety profile when compared to other treatments. You can read more about their pipeline here.

Cash and debt info on SNTA: According to Yahoo Finance, SNTA has about $51 million in cash and about $15 million in debt. The cash balance is equal to about $1.22 per share.

Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) is trading around $7.30. Vanda is a biotechnology company, based in Maryland. These shares have traded in a range between $6.04 to $11.55 in the last 52 weeks. The 50 day moving average is $7.36 and the 200 day moving average is $7.53. VNDA is estimated to lose about 2 cents per share in 2011 and make a profit of 13 cents per share for 2012. In the product development pipeline, Vanda has "Tasimelteon" which is an oral compound for sleep and mood disorders. They also have "Fanapt" which belongs to a class of medications for schizophrenia. You can learn more about their pipeline here.

Cash and debt info on VNDA: According to Yahoo Finance, VNDA has about $198 million in cash and basically no debt. The cash balance is equal to about $7.05 per share.

Repligen Corporation (NASDAQ:RGEN) is trading around $3.90. RGEN is a biotechnology company, based in Massachusetts. These shares have traded in a range between $3 to $5.36 in the last 52 weeks. The 50 day moving average is $4.37 and the 200 day moving average is $3.86 so these shares are trading near key support levels. RGEN is estimated to earn about 4 cents per share in 2011. Repligen recently reported positive results from a phase 3 study for RG1068, which is designed to improve magnetic resonance imaging of the pancreas. You can read more on that here. You can read more about their pipeline here.

Cash and debt info on RGEN: According to Yahoo Finance, RGEN has about $51 million in cash and basically no debt. The cash balance is equal to about $1.66 per share.

Chelsea Therapeutics (NASDAQ:CHTP) is trading around $4. CHTP is a biotechnology company, based in North Carolina. These shares have traded in a range between $1.94 to $8.20 in the last 52 weeks. The 50 day moving average is $4.29 and the 200 day moving average is $4.69. CHTP is estimated to lose about 86 cents per share in 2011. Insiders have been buying CHTP shares. One insider bought 40,000 shares in March, which you can see here. Chelsea is pursuing an orphan drug strategy for a drug called Northera (Droxidopa) which is for the treatment of hypotension. This treatment has been approved and marketed in Japan for over 15 years, and generates about $50 million in revenue in that country. You can read more about this and other key products in their pipeline here.

Cash and debt info on CHTP: According to Yahoo Finance, CHTP has about $47.5 million in cash and basically no debt. The cash balance is equal to about 77 cents per share.

Alimera Sciences (NASDAQ:ALIM), is trading around $8. Alimera is a biotechnology company based in Georgia. These shares have traded in a range between $6.30 to $12.70 in the last 52 weeks. The 50 day moving average is $8.16 and the 200 day moving average is $9.09. ALIM is estimated to lose about 85 cents per share in 2011. This company has a proposed treatment for diabetic macular edema called "Iluvien." This treatment is currently under review by the U.S. FDA and with 7 European health authorities. Alimera also has other key products to treat macular degeneration in the pipeline. You can read more about all of them here.

Cash and debt info on ALIM: According to Yahoo Finance, ALIM has about $55 million in cash and about $5.9 in debt. The cash balance is equal to about $1.45 per share.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is trading around $9.97. ALNY is a biotechnology company, based in Massachusetts. These shares have traded in a range between $8.79 to $17.59 in the last 52 weeks. The 50 day moving average is $10.13 and the 200 day moving average is $12.09. ALNY is estimated to lose about $1.22 per share in 2011 and post a loss of about $1.61 per share for 2012.

In the product development pipeline, Alnylam has candidates for Huntington's disease, liver cancer, RSV infections, anemia and more. You can learn more about their pipeline here.

Cash and debt info on ALNY: According to Yahoo Finance, ALNY has about $233 million in cash and basically no debt. The cash balance is equal to about $5.51 per share.

The data is sourced from Yahoo Finance, Stockcharts.com and Insidercow.com. The information and data is believed to be accurate, but no guarantees or representations are made. Rougemont is not a registered investment advisor and does not provide specific investment advice. The information contained herein is for educational purposes only.

Source: 6 Cash Rich Biotech Stocks With Catalysts